(SCITECHDAILY) -- Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID. The vaccine is based on research carried out at the University of Helsinki and the University of Eastern Finland.
The vaccine uses gene transfer technology developed at the University of Eastern Finland by Academy Professor Seppo Ylä-Herttuala’s research group, and the technology has already been successfully used in several clinical trials using gene therapy to treat cardiovascular diseases and cancer. The vaccine uses a safe adenovirus carrier that contains a cloned DNA strand, which causes nasopharyngeal cells to produce the virus protein which, in turn, produces a response to the vaccine. There is no actual SARS-CoV-2 virus in the vaccine. Preliminary results show that the vaccine has performed well in animal studies, and clinical testing in humans will start within a few months.
Nasal delivery was chosen as the new vaccine’s method of administration because the virus is also naturally transmitted through the airways. Indeed, nasal administration seems to induce a wider immune response than intramuscular administration.
Advertisement - story continues below